Resignation of five general managers of famous pharmaceutical enterprises

The resignation of five general managers of Pfizer: frequent changes in senior executives, changes in the company's organizational structure, business plan and overall style What kind of fate will Pfizer's pharmaceutical agents face in the future? Recently, according to Yao Sila, Pfizer puqiang sent an email, and the company's management decided to make corresponding adjustments to the structure of the business team: the five general managers of the company left collectively, and the former general managers Chen Yuli, Wei Yongfu, Li Xiumei, Yuan Jihong and Zhou Haitao would leave the company to seek external development opportunities (image source: Tesla) Corresponding to this is the appointment and removal of new personnel, with Xiaoxiu as the general manager of retail business, GE Benxing as the general manager of West China business, Xue Peng as the general manager of North China business, ye Wei as the general manager of South China business, Li Junjie as the general manager of East China business, and Jin Tianjun as the general manager of East China business All of the above report directly to Mr Huang Hai, chief operating officer of puqiang China In addition, jusra also disclosed a series of subsequent operational decisions of puqiang: 1 Pu Qiang will no longer set up a director, and the new general manager will directly lead the region 2 The compensation policy is n + 1 + 2 The remaining areas are 6-9 months, the regions are 3-6 months, the specialists are 3 months, and the length of service is continued 3 In order to boost morale, the company's annual meeting may be changed from Zhuhai to Australia In fact, as early as September 10, Gao Tianlei, global president of Pfizer, announced to employees that Wu Feng, general manager of Pfizer in China, would leave his post and seek other career development opportunities On the same day, Yellow Sea, the head of China's market, served as the chief operating officer of puqiang China and was responsible for the market and sales In a few months, with frequent changes of senior executives, the company's organizational structure, business plan and overall style will change to some extent Pfizer said in an email: Despite a series of challenges such as external volume purchasing and internal structure restructuring, we still maintain the continuous growth of our business under the premise of compliance with your joint efforts Next, several newly appointed business general managers will work with you to plan the next organizational structure and business plan I hope you can actively cooperate with and support their work to ensure a smooth transition of business In recent months, Pfizer has been constantly changing Due to the merger of Pfizer and mylan, the reorganization of the company's sales position is also the focus of employees Sepiland learned from the insiders that Pfizer will complete the negotiation of all severance compensation at the end of November, and the total number of severance employees is n (working years) + 1 + 2 Where "+ 1" refers to the sum of all income before tax divided by 12 and "+ 2" refers to basic wage * 2 The remaining companies will belong to the company after the merger of puqiang and Meilan, and the new company will be established by the middle of next year To some extent, the reorganization of the two companies will inevitably bring about job changes of some employees It has become the practice of many enterprises to retain the "key talents" of the two companies - on the surface, the merger of the two large pharmaceutical companies, but the subdivision of them will have a profound impact on each of them After all, Pfizer has more than 5000 employees in China and has set up a pharmaceutical factory in Dalian A medical representative once wrote on the social network: Pfizer is Pfizer, puqiang is puqiang No matter you are cut or transferred to puqiang, you have no relationship with Pfizer The only hope is to get together with Pfizer Because mylan is a imitated pharmaceutical company, the salary level is not as high as Pfizer All the pharmaceutical representatives involved in it will also face changes in the salary level and indicators There was a view in the industry that the merger of Pfizer and mylan was a warm embrace under the policy collapse Pfizer's announcement also indirectly shows this: by combining two highly complementary businesses, new companies will transform and accelerate their business capabilities to meet the needs of patients, and expand their capabilities in more than 165 markets It is understood that mylan is a non patent medicine and specialty medicine manufacturing company, and has become the second largest generic medicine manufacturer in the world since it acquired the generic medicine business of matrix Laboratories Limited, an Indian pharmaceutical company, and Merck, a German pharmaceutical company, in 2007 In this merger, mylan will bring a diversified product portfolio for key treatment areas, such as central nervous system and anesthesia, infectious diseases and cardiovascular diseases, as well as strong product pipeline, high-quality manufacturing and supply chain advantages Puqiang will bring iconic brands such as Lipitor (atorvastatin calcium), Celebrex (celecoxib) and Viagra (sildenafil), as well as proven commercialization capabilities, including leadership in China and other emerging markets Previously, because the patent cliff of the original research drug in China was delayed, its profits were basically from the abnormal premium of China, the world's largest emerging market As the first foreign enterprise to set up a global management team in China, Pfizer puqiang has 20 most iconic mature pharmaceutical brands covering a number of disease areas It will be headquartered in Shanghai, and also has a good eye on the Chinese market.